The Center for Biosimilars® recaps the top 5 articles for the week of April 23, 2018.
Transcript:
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of April 23.
Number 5: A recent report demonstrates that there is unequal access to biologics and biosimilars for the treatment of inflammatory bowel disease among nations and regions worldwide.
Number 4: Australia’s Therapeutic Goods Administration has approved Celltrion’s rituximab biosimilar.
Number 3: The FDA’s Arthritis Advisory Committee recommended approval of only 1 of 2 proposed doses of baricitinib, a drug that many believed could compete for market share with Humira.
Number 2: A patient advocacy group is asking the Federal Trade Commission to investigate whether AbbVie’s recent settlements concerning patents on Humira violate the law.
Number 1: The Supreme Court of the United States ruled this week that the inter partes review process, which many biosimilar developers use to challenge patents on biologics, is constitutional.
Finally, last week, our e-newsletter asked whether you think that nurses are getting enough education about biosimilars.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.